Your selection
NoneFilter by content type
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Update on Regulatory Review of Aducanumab in the European Union
November 17, 2021 - … the two defining pathologies of Alzheimer’s disease. About ADUHELM ™ (aducanumab-avwa) injection 100 mg/mL solution ADUHELM is indicated for the treatment of Alzheimer’s disease in the United States. Treatment with ADUHELM should be initiated in patients with mild cognitive …
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
March 30, 2022 - … Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA … is a requirement based on FDA’s accelerated approval of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for …
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
January 27, 2022 - … Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM® Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM® January 27, 2022 News Release General CAMBRIDGE, … Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for …
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
July 26, 2021 - … Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s … International Conference 2021 Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s … disease and clinical decline after treatment with ADUHELM Presentation on ARIA data from Phase 3 trials …
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
September 21, 2021 - … Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline … Alzheimer’s disease pipeline with the recent FDA-approved ADUHELM serving as the foundation of a multi-target, … Alzheimer’s disease franchise. In addition to ADUHELM, the company will present progress on lecanemab …
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
March 11, 2022 - … new Alzheimer’s disease research, as well as data for ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for … on March 16, will include an examination of the ability of ADUHELM to reduce amyloid beta plaque and plasma p-tau181, … endpoints during the long-term extension phase of the ADUHELM clinical program. An oral presentation on March 18, …
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
November 3, 2021 - … 3, 2021 News Release General Late breaker will show ADUHELM™ effect on plasma pTau181 reduction, and its … in Phase 3 trials and approximately 1,700 patients in the ADUHELM (aducanumab-avwa) redosing trial, EMBARK. A late … important new data from over 7,000 plasma samples from the ADUHELM Phase 3 trials that, for the first time, examines the …
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024 - … General Company to reprioritize resources allocated to ADUHELM ® (aducanumab-avwa) to advance LEQEMBI ® … will discontinue the development and commercialization of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for … the resources released resulting from termination of the ADUHELM program will be redeployed in Biogen’s AD franchise. …
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
March 14, 2022 - … which is commercialized in the United States as ADUHELM ® (aducanumab-avwa). Effective as of January 1, 2023, … Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. The … Biogen’s existing final decision-making rights on ADUHELM have converted to sole decision making and …
Corporate Statement on Report by the Staffs of the Committee on Oversight and Reform and Committee on Energy and Commerce
December 29, 2022 - … regarding their investigations into the launch of Aduhelm, including providing requested information. Today, … and we have learned from the development and launch of Aduhelm. That process is continuing to inform our work as … regarding their investigations into the launch of Aduhelm, including providing requested information. … …
- Previous page ‹‹
- Page 3
- Next page ››